Posts Tagged ‘MB12’

Pretty pictures from qEEGs and what they show.

Monday, August 22nd, 2011

As written by Rick Neubrander

Face it, we all like pretty pictures. Nice even colors. Symmetry. No jagged lines. The beauty of a grassy hill. Well, this post is going to be all about pretty pictures.

Many parents come to me and ask, “How do I know if a treatment works? What proof do you have other than an anecdotal story?”  This is where we can show them some of the information we have gathered using qEEG scans.

A qEEG is an EEG which is compared against a database of “normal” EEGs and a graph (pretty pictures) is made showing standard deviations from normal. A normal qEEG would be colored green. Those sections of the brain having too much activity would move towards red. Areas of under-activity would move towards blue. Areas of the brain that do not connect properly are graphed as lines. The thicker the line, the more severe the problem. Therefore, for this first blog all you need to know to be certified as an expert in QEEG interpretation is that GREEN IS GOOD – LINES ARE BAD!

The pictures you will see are drawn over the image of a head. As you look at each “head map”, remember that you are looking down from above. Because the pictures are so small to see clearly, note that the little bump at the top of each picture is the nose and the bumps on the sides represent the ears. As you look at the pictures, you will see that there are five rows and five columns. The meaning of each of these rows and columns is something that we will discuss in more detail in future posts. For now, all you have to know is that a “Q” is looking for several different types of abnormalities in each of these five rows and five columns. These abnormalities will be represented by colors other than green and lines that are either red or blue.

Remember that green is good and lines are bad. Therefore, the qEEG shown below is that of a fairly “normal” brain. A peaceful picture.



The next picture is a common qEEG pattern seen in children with autism.  The picture is filled with ragged reds and blasé blues. It is a picture filled with many angry red and blue lines.


I will, over several blog entries, show some qEEGs in a Before and After Format. To start,  I will post a before and after picture of a child doing our 6 week “trial” of MB12. The left side of the picture is the “before” image and the right is the “after” image. This “Q” is of a child using our MB12 every 3 day protocol during which absolutely no other changes were allowed other than the addition of methyl-B12. Improvements were evident in the areas of language, cognition, and socialization. Notice the reduction of the reds and the greening of the blues. Finally look at the loss of the problematic lines.


Aaahhh, we all like pretty pictures, especially pictures of success stories.  In the picture that follows, you will see a before picture that demonstrates the blank stare so many children on the autism spectrum share. We call this look “Autism Eyes”. Then, for many kids, after they are treated for medical issues by the biomedical methods we use, we get a different look that we call “Autism Byes”.


Hopefully these articles will let you see that biomed is not voodoo science but has actual reproducible scientific evidence of benefit. Stay tuned. More pretty pictures to come!


MB12 and Rats. Why do we care?

Tuesday, August 9th, 2011

This post will be my last for the present time on MB12. I will most likely return to this subject at a later date but I do not wish to lose the attention of my readers and so the next post will be on some of the other treatments we use at the clinic. But for today, I wish to focus on what Dr. Neubrander terms “A Really Cool Rat Study”.

So why would he get so excited about a study done on rats and what does it mean for the patient? Since 2002 Dr. Neubrander has been saying the MB12 given in high doses as an injection makes a difference for children with ASD. For several years it was his observations and parent anecdotes as the only confirmation that MB12 could make a difference. That all changed when this rat study came out. Now there is a  bit of vindication for justifying the use of MB12 but with a slight drawback; the study did not mention autism. Through this study the benefits of MB12 on nerve and nerve repair is shown and may provide an insight into why it works on autism, but as usual, ‘more study is needed’.

I am including a comment that Dr. Neubrander gives to patients regarding the Okada study.

Please note that at the end of this comment I am including the abstract from a recent publication showing that the methyl analog from the cobalamin “family” (methyl, adenosyl, hydroxy, cyano, glutathionyl, and sulfito cobalamin) is the one that is the most biologically active. What is important to me from the article itself, not the abstract, is that though the methyl form is the most biologically active form, it is short-lived and the authors say that possibly a better delivery system is needed, e.g. “injections”. They also say that greater benefits or benefits at all are seen at the higher doses. I have been saying these exact same things for years — injections and daily shots!

Richard Deth, Ph.D. from Northeastern University in Boston, professor, colleague, and friend of mine dealing with the methylation phenomenon, is a world-renowned researcher in methionine synthase. As you know, methylcobalamin is the form of B12 that works hand-in-glove with methionine synthase. On March 31, 2010, Dr. Deth commented on the Okada article: “Although the article (Okada et al.) is basic science, it does provide some important insights into the effects of methyl-B12 (MeB12) on neurons and how it does it. Using neurons from rats, they showed that MeB12 increases the length of axons, the formation of neurites, and increases resistance to apoptosis. Together these effects indicate a significant role in development of networks among neurons. MeB12 was the best form of cobalamin for doing this, although others had activity, presumably because they were converted to MeCbl. They also showed that the effects of MeB12 reflected increased methylation, and adding SAM had similar, but weaker effects. MeB12 increased activation of the MAP kinase and PI3 kinase signaling pathways, indicating that it mimics the effects of neurotrophic growth factors. Finally, MeB12 improved the repair of transsected nerves as well as improved functional recovery of motor activity, in conjunction with increased myelination. All together a pretty impressive array of effects.“


The abstract on this study I posted below. You can look it up on pubmed, but I am listing it here for your convenience.

Exp Neurol. 2010 Apr;222(2):191-203. Epub 2010 Jan 4.

Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model.

Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, Murase T, Yoshikawa H.
Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Methylcobalamin is a vitamin B12 analog and is necessary for the maintenance of the nervous system. Although some previous studies have referred to the effects of methylcobalamin on neurons, the precise mechanism of this effect remains obscure. Here we show that methylcobalamin at concentrations above 100 nM promotes neurite outgrowth and neuronal survival and that these effects are mediated by the methylation cycle, a metabolic pathway involving methylation reactions. We also demonstrate that methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle. In a rat sciatic nerve injury model, continuous administration of high doses of methylcobalamin improves nerve regeneration and functional recovery. Therefore, methylcobalamin may provide the basis for better treatments of nervous disorders through effective systemic or local delivery of high doses of methylcobalamin to target organs. Copyright 2009 Elsevier Inc. All rights reserved.
PMID: 20045411 [PubMed - indexed for MEDLINE]


Glutathione and MB12. Is there a connection?

Friday, August 5th, 2011

Methylation and Transsulfuration PathwaysIn continuing the series on the use of MB12 in autism, I am going to discuss the role of MTHFR and Glutathione. The last article showed that the MTHFR mutation is more common in people with ASD than in the regular population. The study listed below makes a correlation between MTHFR and low levels of Glutathione in the blood.

Experimental Biology 2005. April 2. San Diego . Abstract

Low plasma methionine, cysteine, and glutathione levels are associated with increased frequency of common polymorphisms affecting methylation and glutathione pathways in children with autism

S. Jill James, Stepan Melnyk, Stefanie Jernigan. Pediatrics, University of Arkansas for Medical Sciences, 1120 Marshall St. , Slot 512.40B, Little Rock , AR , 72202

Autism is a complex neurodevelopmental disorder that is thought to involve both genetic and environmental factors. The 10-fold increase in the prevalence of autism in the last 15 years is a major public health concern. Although abnormal thiol metabolism has been associated with other neurologic diseases, these pathways and related polymorphisms have not been evaluated in autistic children. Plasma levels of metabolites in methionine transmethylation and transsulfuration pathways were measured in 90 autistic and 45 control children using HPLC with electrochemical detection. Polymorphic variants in transcobalamin II (TCII), methylene- tetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR), catecholamine-O-methyltransferase (COMT), and glutathione-S-transferase (GST) M1/T1 were evaluated in 233 autistic children and 183 controls. The results indicated that mean levels of methionine, cysteine, total glutathione, and the ratio of oxidized to reduced glutathione were significantly decreased among the autistic children. The frequency of MTHFR 677CT/1298AG heterozygosity, TCII 776GG, COMT 1947GG, and the GST M1/T1 double null genotype was increased in the autistic children relative to controls. We hypothesize that an increased vulnerability to oxidative stress (environmental and/or intracellular) may contribute to the development and clinical manifestations of autism.


So what does this mean for a patient? Glutathione is the body’s natural detoxification mechanism. Its job is to move ‘bad stuff’ out of the body. If you do not have enough, then harmful substances can accumulate and thus affect health; or if the toxins get too high, they can affect brain function. So how does glutathione affect the brain and what does this have to do with MB12? The following is a comment that Dr. Neubrander gives to his patients that (while a bit technical) may explain some of the processes involved.


According to the work of Dr. Richard Deth, methyl-B12 seems to work better in the brain, especially the cortex, than it does in the liver. This is probably because glutathione is very abundant in the liver but limited in the brain and methionine synthase in the brain is configured differently than in the liver.  The methyl-B12-requiring form of the methionine synthase enzyme will only be active when there is enough glutathione around to synthesize methyl-B12. Of course the first step is the conversion of hydroxy-B12 to glutathionyl-B12. This occurs spontaneously when hyroxy-B12 and glutathione are simply mixed together.  It’s limited only by the glutathione level, which is how nature designed it. So in tissues like the brain (neurons) where glutathione is scarce, methionine synthase activity will only be turned on when glutathione is adequate. Otherwise homocysteine will be continuously diverted toward glutathione synthesis.  Thus methylation (i.e. D4 receptor activity) in the brain is only allowed to occur when there is enough glutathione.  Things that lower glutathione (e.g. mercury) will therefore particularly lower methylation activity in the brain. SAM is also required for methyl-B12 synthesis, but does not seem to be as critical a limiting factor as glutathione.

At least theoretically, there could indeed be people for whom hydroxy-B12 might be better than methyl-B12. Making methyl-B12 available all the time removes the glutathione contingency for methionine synthase activity.  It does guarantee that the D4 receptor phospholipid methylation mechanism will always be operating at better efficiency, despite lower glutathione levels, which is probably the main cognitive benefit of methyl-B12. However, allowing hydroxy-B12 to be converted to glutathionyl-B12 by glutathione may be important for other aspects of methylation.  For example, consider DNA methylation. When methionine synthase stays turned off, homocysteine and SAH accumulate. The SAH will inhibit DNA methylation and “turn on” some genes that used to be silenced by methylation. Some of these genes may serve a useful role in combating oxidative stress.  When methyl-B12 is given it will tend to lower homocysteine and SAH, which will tend to increase DNA methylation. Of course at this time we can only speculate about what genes might be involved, so this is just a theoretical perspective.

In general there is the possibility that too much methyl-B12 could be a problem, so finding the right dose and right duration of therapy for a given individual remains an important consideration. Hopefully in the near future there will be laboratory tests allowing us to discriminate between who needs methyl-B12 or hydroxy-B12 and who doesn’t.



Why is Methyl-B12 stressed at our clinic and how does it help kids with ASD?

Wednesday, August 3rd, 2011

Image showing how MTHFR and Methionine Synthase interact.Since May of 2002, Dr. Neubrander has been stressing the importance of MB12 for children on the spectrum. His initial finding of MB12′s benefits came by accident. In treating a non-verbal  seven-year-old autistic patient, he decided to try a new form of B12 to help with some of the nutritional issues seen in this particular patient. One week later, in the middle of a huge storm that was hitting New Jersey, the parents of that child came unannounced to the office and ran down the hall shouting, “What was that you gave our child? He started speaking!” Thus history was made that day.

So why does MB12 help so many on the spectrum? This first series of blog posts will go through the various aspects of why MB12 is needed and how it helps. To start the series, I will be getting a little scientific but hopefully can explain it in such a way that an ordinary, non-medical person can understand.

First I am going to discuss the MTHFR mutation.  I will probably be touching on this subject in future posts, but today I will start off with one study showing that people with ASD have a higher rate of mutation in the MTHFR gene, and then will follow with the doctor’s explanation of how this impacts persons with the mutation.  Dr. Neubrander has written a preface for the study that we give our patients and I will begin with that comment, follow with the abstract, and end with an explanation of what this means in lay-terms.

JUNE 2009:  Preface by Dr. Neubrander to the following published study  –   Please note that in my practice I have been testing most patients for MTHFR and homocysteine status.  Though I have not yet officially tabulated the results from my patient population, I can definitely say by “seat-of-the-pants science” that the incidence of the MTHFR mutations, whether C677T or A1298C, are much higher than what was reported in this study.  I can also say that most of my patients have at least one mutation; many have two.  It has been my observation that children with the C677T homozygous (double) mutation are the most likely to respond to MB12 and with some of the best “initial intensities of response”.  Children who have a single (heterozygous) mutation of the C677T allele or who have two single mutations on the two different alleles, C677T (heterozygous) and A1298C (heterozygous) or who have double mutations (homozygous) of the A1298 allele are the next most likely group of children to respond  to MB12 injections.  As a general rule, this group of children demonstrate responses fewer in number and of a lesser intensity when present. Children with a single (heterozygous) mutation of the A1298C allele represent the group of children whose responses, though present, are usually the fewest in number and of the least intensity.  It is interesting to hypothesize why some of the best responders, both in number of responses and intensity of responses, have no MTHFR mutations.

Psychiatr Genet. 2009 May 13. [Epub ahead of print]
Aberrations in folate metabolic pathway and altered susceptibility to autism.

Mohammad NS, Jain JM, Chintakindi KP, Singh RP, Naik U, Akella RR.

a. Center for DNA Fingerprinting and Diagnostics
b.Institute of Child Health, Niloufer Hospital, Hyderabad, India.

OBJECTIVE: To investigate whether genetic polymorphisms are the underlying causes for aberrations in folate pathway that was reported in autistic children. BASIC METHODS: A total of 138 children diagnosed as autistic based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria and Autism Behavior Checklist scoring and 138 age and sex matched children who are nonautistic were tested for five genetic polymorphisms, that is, cytosolic serine hydroxyl methyl transferase (SHMT1 C1420T), methylene tetrahydrofolate reductase (MTHFR C677T and MTHFR A1298C), methionine synthase reductase (MTRR A66G), methionine synthase (MS A2756G) using PCR-restriction fragment length polymorphism methods. Fisher’s exact test and logistic regression analysis were used for statistical analyses. RESULTS: MTHFR 677T-allele frequency was found to be higher in autistic children compared with nonautistic children (16.3 vs. 6.5%) with 2.79-fold increased risk for autism [95% confidence interval (CI): 1.58-4.93]. The frequencies of MTRR 66A allele (12.7 vs. 21.0%) and SHMT 1420T allele (27.9 vs. 45.3%) were lower in autistic group compared with nonautistic group with odds ratios 0.55 (95% CI: 0.35-0.86) and 0.44 (95% CI: 0.31-0.62), respectively, indicating reduced risk. MTHFR 1298C-allele frequency was similar in both the groups (53.3 vs. 53.6%) and hence individually not associated with any risk. However, this allele was found to act additively in the presence of MTHFR 677T allele as evidenced by 8.11-fold (95% CI: 2.84-22.92) risk associated with MTHFR 677CT+TT/1298AC+CC genotypes cumulatively. CONCLUSION: MTHFR C677T is a risk factor, whereas MTRR A66G and SHMT C1420T polymorphisms reduce risk for autism. MTHFR A1298C acts additively in increasing the risk for autism.


So what does this mean? Of what importance is MTHFR to ASD? I am including a comment we give our patients to explain in simpler terms what MTHFR does.

The way that the MTHFR enzymatic defect fits into this whole scenario is that folic acid family members from food must travel down a biochemical pathway and present itself to the enzyme MTHFR [methyltetrahydrofolate reductase].  This enzyme then will catalyze the biochemical reaction that allows the precursor “unmethylated” folic acid molecule to grab onto extra hydrogen atoms and now become a “methylated” folic acid molecule [5-methyltetrahyrdofolic acid].  It is the methyl group from this methylated folic acid molecule that can now donate the methyl group to “rabbit B12″ — the plain ole’ ordinary B12 that comes from food or supplements – so that rabbit B12 now becomes “methyl”-B12.  It is this methyl-B12, whose methyl group originated from the “MTHFR processing plant”, that will react with the enzyme methionine synthase to go on to donate this same methyl group to homocysteine to now become “methylated homocysteine” whose “other name” is methionine.  It is this methionine that moves on to eventually donate this same methyl group to the brain to make proper functioning RNA, DNA, neurotransmitters, speech and language molecules [creatine], and nervous signal synchronization molecules [phospholipids].  Once this methyl group has been donated, the “methyl carrier molecule — metabolic smoke” eventually winds up to become homocysteine again.  Once homocysteine is formed, it acts like a traffic cop deciding to send traffic to the left or to the right.  “About” half the time homocysteine goes back to get another methyl group from “the next” methyl-B12 that shows up as the process described above repeats itself.  “About” the other half of the time homocysteine decides to become glutathione which is the body’s major intracellular antioxidant and one of the body’s major way to detoxify many types of poison, only one of which is mercury.

The MTHFR enzyme has legs just like we have legs.  We call our legs “left leg — right leg”.  On both legs we are supposed to have ankles and knees.  MTHFR’s legs have funny names.  The name of one leg is C677T and the name of the other leg is A1298T.  The name of MTHFR’s ankles and legs are C and T or A and T.  Now here’s what’s happening.  When we try to run, we do very well if we have two legs with knees and ankles.  If we have an amputation of one ankle, we can still get around but we will definitely be slowed down.  If we have an amputation above the knee, we will still be able to get around but much, much slower.  If we had an amputation of a knee or ankle on the other leg, once again we would get around much, much slower.  So it is with the ankles and legs on the MTHFR enzyme.  If there is a single mutation, called heterozygous, one of the legs will have been amputated at the ankle.  It there is a double mutation on the same leg, called homozygous, that leg will have been amputated above the knee.  Combinations of heterozygous and homozygous mutations [analogous here to "amputations"] can occur.

What the developing research is finding is that mutations of the MTHFR enzyme occur quite frequently in children on the autistic spectrum.  Therefore, as you can now see, these children will have a “slowed ability” to produce the methylated folic acid molecules that are required to form “enough” methyl-B12 at the rate necessary to make “brain things” and to make “detoxification things”.  Therefore, in order to bypass this defect, methyl-B12 must be administered on a continual steady-state basisThis is the reason that injectable methyl-B12 into the subcutaneous tissue accomplishes this goal.  By being in the subcutaneous tissue it slowly leaches out and provides a continual supply of “just a little bit” of methyl-B12 to be available for methionine synthase to use to recycle homocysteine.